Verubecestat

Drug Profile

Verubecestat

Alternative Names: MK-8931; SCH-900931

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antidementias; Fluorobenzenes; Pyridines; Small molecules; Thiadiazines
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 16 Jul 2017 Pharmacodynamics data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 12 Apr 2017 Merck Sharp & Dohme completes a two-part phase I pharmacokinetics trial in USA (PO, Tablet) (NCT02910739)
  • 28 Feb 2017 Merck has patent protection for verubecestat in USA (Merck Annual report 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top